Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis

• Autors principals: Ju Li (Autor), Zhongyuan Zhang (Autor), Xinhua Wu (Autor), Jie Zhou (Autor), Deqian Meng (Autor), Ping Zhu (Autor)
• Format: Llibre
• Publicat: Frontiers Media S.A., 2021-11-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Background: Adalimumab, golimumab, infliximab, certolizumab, and etanercept are five anti-tumor necrosis factor (anti-TNF) medicines that have been approved for use in rheumatology. Apart from their well-established therapeutic usefulness, -it is unclear to what extent -they are linked to an increas...